TEAM (Trial on Efficacy and Quality of Life Among Asthmatic Patient With Montelukast)

Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.

Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured